Interacciones de Ipratropio

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Hypersensitivity to ipratropium bromide or other ATROVENT HFA components Hypersensitivity to atropine or any of its derivatives Hypersensitivity to ipratropium bromide or other ATROVENT HFA components ( 4 ) (etiqueta de Ipratropio, Contraindicaciones)

Hypersensitivity to ipratropium bromide or other ATROVENT HFA components Hypersensitivity to atropine or any of its derivatives Hypersensitivity to ipratropium bromide or other ATROVENT HFA components ( 4 ) (etiqueta de Ipratropio, Contraindicaciones)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. (etiqueta de Citrato de potasio, Contraindicaciones)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Hypersensitivity to ipratropium bromide or other ATROVENT HFA components Hypersensitivity to atropine or any of its derivatives Hypersensitivity to ipratropium bromide or other ATROVENT HFA components ( 4 ) (etiqueta de Ipratropio, Contraindicaciones)

Hypersensitivity to ipratropium bromide or other ATROVENT HFA components Hypersensitivity to atropine or any of its derivatives Hypersensitivity to ipratropium bromide or other ATROVENT HFA components ( 4 ) (etiqueta de Ipratropio, Contraindicaciones)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Hypersensitivity to ipratropium bromide or other ATROVENT HFA components Hypersensitivity to atropine or any of its derivatives Hypersensitivity to ipratropium bromide or other ATROVENT HFA components ( 4 ) (etiqueta de Ipratropio, Contraindicaciones)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, malignant hyperthermia, drug fever, serotonin syndrome, and primary central nervous system pathology. (etiqueta de Metoclopramida, Advertencias y precauciones)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent. (etiqueta de Quinidina, Contraindicaciones)

IF INITIATION OF AEROSOLIZED RIBAVIRIN FOR INHALATION SOLUTION, USP TREATMENT APPEARS TO PRODUCE SUDDEN DETERIORATION OF RESPIRATORY FUNCTION, TREATMENT SHOULD BE STOPPED AND REINSTITUTED ONLY WITH EXTREME CAUTION, CONTINUOUS MONITORING AND CONSIDERATION OF CONCOMITANT ADMINISTRATION OF BRONCHODILATORS (SEE WARNINGS ). (etiqueta de Ribavirina, Advertencia en recuadro)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (etiqueta de Rivastigmina, Interacciones medicamentosas)

Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

Other short-acting sympathomimetic aerosol bronchodilators should not be used concomitantly with albuterol. (etiqueta de Salbutamol, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

…(HR) b or Serotonin Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension… (etiqueta de Tranilcipromina, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (etiqueta de Ipratropio, Interacciones medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etiqueta de Aripiprazol, Advertencias y precauciones)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use SAPHRIS with caution in patient who may experience these conditions. (etiqueta de Asenapina, Advertencias y precauciones)

Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (etiqueta de Atenolol, Advertencias)

Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (etiqueta de Atenolol y clortalidona, Advertencias)

Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (etiqueta de Aztreonam, Advertencias y precauciones)

Drugs that alter gastrointestinal motility: The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g., atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. (etiqueta de Benazepril e hidroclorotiazida, Interacciones medicamentosas)

Since β 1 -selectivity is not absolute and is inversely related to dose, the lowest possible dose of betaxolol should be used (5 to 10 mg once daily) and a bronchodilator should be made available. (etiqueta de Betaxolol, Advertencias)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (etiqueta de Brexpiprazol, Advertencias y precauciones)

Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Buprenorfina, Interacciones medicamentosas)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Buprenorfina y naloxona, Interacciones medicamentosas)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Butalbital, ácido acetilsalicílico, cafeína y codeína, Interacciones medicamentosas)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Butalbital, paracetamol, cafeína y codeína, Interacciones medicamentosas)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etiqueta de Carbamazepina, Advertencias y precauciones)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (etiqueta de Carbidopa, Advertencias)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use VRAYLAR with caution in patient who may experience these conditions. (etiqueta de Cariprazina, Advertencias y precauciones)

Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with ALVESCO. (etiqueta de Ciclesonida, Advertencias y precauciones)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Codeína, Interacciones medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etiqueta de Deutetrabenazina, Advertencias y precauciones)

The intravenous administration of anticholinergic agents (e.g., glycopyrrolate, atropine) should be considered to modify vagal tone. (etiqueta de Dexmedetomidina, Advertencias y precauciones)

Anticholinergic effects of quinidine: Monitor for worsening in myasthenia gravis and other sensitive conditions. (etiqueta de Dextrometorfano y quinidina, Advertencias y precauciones)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (etiqueta de Dronabinol, Advertencias y precauciones)

Examples: alosetron, anticholinergics, opioids Table 3: Established and Other Potentially Clinically Relevant Interactions Affecting Drugs Co-Administered with VIBERZI OATP1B1 and BCRP Substrate Clinical Impact: VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates. (etiqueta de Eluxadolina, Interacciones medicamentosas)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Fentanilo, Interacciones medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (etiqueta de Flufenazina, Advertencias)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (etiqueta de Haloperidol, Advertencias)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Hidrocodona, Interacciones medicamentosas)

Anticholinergics The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Hidrocodona e ibuprofeno, Interacciones medicamentosas)

Anticholinergic Drugs The concomitant use of anticholinergic drugs with hydrocodone bitartrate and homatropine methylbromide may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus [see Warnings and Precautions (5.9) ] . (etiqueta de Hidrocodona y homatropina, Interacciones medicamentosas)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Hidrocodona y paracetamol, Interacciones medicamentosas)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Hidromorfona, Interacciones medicamentosas)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use FANAPT with caution in patients who may experience these conditions. (etiqueta de Iloperidona, Advertencias y precauciones)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Levorfanol, Interacciones medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (etiqueta de Loxapina, Advertencias)

Interrupt MARGENZA infusion in patients experiencing dyspnea or clinically significant hypotension and intervene with medical therapy which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators and oxygen. (etiqueta de Margetuximab, Advertencias y precauciones)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Metadona, Interacciones medicamentosas)

Bronchodilators, including beta 2 -agonists, should be readily available or administered concomitantly [see Dosage and Administration (2) ]. (etiqueta de Metoprolol, Advertencias y precauciones)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (etiqueta de Metoprolol e hidroclorotiazida, Advertencias y precauciones)

• Urinary Retention in Patients With Bladder Outlet Obstruction and in Patients Taking Muscarinic Antagonist Drugs for Overactive Bladder : Administer with caution in these patients because of risk of urinary retention. (etiqueta de Mirabegrón, Advertencias y precauciones)

In a 2-year double-blind study in 103 male and female asthma patients 18 to 50 years of age previously maintained on bronchodilator therapy (Baseline FEV 1 85%-88% predicted), treatment with mometasone furoate dry powder inhaler 200 mcg twice daily resulted in significant reductions in lumbar spine (LS) BMD at the end of the treatment period compared to placebo. (etiqueta de Mometasona, Advertencias y precauciones)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Morfina, Interacciones medicamentosas)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Nalbufina, Interacciones medicamentosas)

An anticholinergic agent, (e.g., atropine sulfate or glycopyrrolate) should be administered prior to Neostigmine Methylsulfate Injection administration to lessen the risk of bradycardia [ see Dosage and Administration ( 2.4 ) ]. (etiqueta de Neostigmina, Advertencias y precauciones)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Oliceridina, Interacciones medicamentosas)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Oxicodona, Interacciones medicamentosas)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Oxicodona y paracetamol, Interacciones medicamentosas)

Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Oximorfona, Interacciones medicamentosas)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Paracetamol y codeína, Interacciones medicamentosas)

Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Pentazocina y naloxona, Interacciones medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (etiqueta de Perfenazina, Advertencias)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Petidina (meperidina), Interacciones medicamentosas)

These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium). (etiqueta de Pilocarpina, Interacciones medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (etiqueta de Pimozida, Advertencias)

Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (etiqueta de Piridostigmina, Advertencias y precauciones)

Anticholinergic drugs administered concurrently with PA may produce additive antivagal effects on A-V nodal conduction, although this is not as well documented for PA as for quinidine. (etiqueta de Procainamida, Interacciones medicamentosas)

The intravenous administration of anticholinergic agents (e.g., atropine or glycopyrrolate) should be considered to modify potential increases in vagal tone due to concomitant agents (e.g., succinylcholine) or surgical stimuli. (etiqueta de Propofol, Advertencias y precauciones)

• Anticholinergic (antimuscarinic) Effects: Use with caution with other anticholinergic drugs and in patients with urinary retention, prostatic hypertrophy, or constipation (5.20) (etiqueta de Quetiapina, Advertencias y precauciones)

Bronchodilator: theophylline ↓ theophylline Increased dosage of theophylline may be required; therapeutic monitoring should be considered. (etiqueta de Ritonavir, Interacciones medicamentosas)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (etiqueta de Sevoflurano, Advertencias)

Monitor for hemodynamic changes and administer anticholinergic agents such as atropine if clinically significant bradycardia is observed. (etiqueta de Sugammadex, Advertencias y precauciones)

Pretreatment with anticholinergic agents (e.g., atropine) may reduce the occurrence of bradyarrhythmias. (etiqueta de Suxametonio (succinilcolina), Advertencias y precauciones)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Tapentadol, Interacciones medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etiqueta de Tetrabenazina, Advertencias y precauciones)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (etiqueta de Tiotixeno, Advertencias)

Caution should be used when topiramate extended-release capsules are prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity. (etiqueta de Topiramato, Advertencias y precauciones)

Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (etiqueta de Toxina botulínica tipo A, Interacciones medicamentosas)

Because of its anticholinergic effects, XEOMIN should be used with caution in patients at risk of developing narrow angle glaucoma. (etiqueta de Toxina incobotulínica A, Advertencias y precauciones)

Anticholinergic Drugs Use of anticholinergic drugs after administration of BOTOX may potentiate systemic anticholinergic effects. (etiqueta de Toxina onabotulínica A, Interacciones medicamentosas)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Tramadol, Interacciones medicamentosas)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Tramadol y paracetamol, Interacciones medicamentosas)

Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (etiqueta de Trifluoperazina, Advertencias)

The recent use of other drugs that cause CNS depression or EPS symptoms (e.g., alcohol, sedatives, hypnotics, opiates, anxiolytics, antipsychotics, and anticholinergics) may also increase the risk for these serious CNS reactions [see Warnings and Precautions ( 5.1 , 5.5 )] . (etiqueta de Trimetobenzamida, Advertencias y precauciones)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etiqueta de Valbenazina, Advertencias y precauciones)

Urinary Retention : Monitor for urinary retention, especially in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for OAB, in whom the risk of urinary retention may be greater. (etiqueta de Vibegrón, Advertencias y precauciones)

If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (etiqueta de Zanamivir, Advertencias y precauciones)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (etiqueta de Ziprasidona, Advertencias y precauciones)

Caution should be used when ZONISADE is prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, carbonic anhydrase inhibitors and drugs with anticholinergic activity. (etiqueta de Zonisamida, Advertencias y precauciones)

A bronchodilator, such as theophylline or a β2-stimulant, should be made available in advance with instructions concerning its use. (etiqueta de Acebutolol, Advertencias)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (etiqueta de Ipratropio, Advertencias y precauciones)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (etiqueta de Ipratropio, Advertencias y precauciones)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etiqueta de Bevacizumab, Advertencias y precauciones)

A beta 2 agonist (bronchodilator) should be made available. (etiqueta de Bisoprolol, Advertencias)

A beta 2 agonist (bronchodilator) should be made available. (etiqueta de Bisoprolol e hidroclorotiazida, Advertencias)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (etiqueta de Ipratropio, Advertencias y precauciones)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly. (etiqueta de Cevimelina, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the C max of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to… (etiqueta de Clonazepam, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

Cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etiqueta de Donepezilo, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

Flumazenil is not recommended in cases of serious cyclic antidepressant poisoning, as manifested by motor abnormalities (twitching, rigidity, focal seizure), dysrhythmia (wide QRS, ventricular dysrhythmia, heart block), anticholinergic signs (mydriasis, dry mucosa, hypoperistalsis), and cardiovascular collapse at presentation. (etiqueta de Flumazenilo, Advertencias)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (etiqueta de Ipratropio, Advertencias y precauciones)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (etiqueta de Ipratropio, Advertencias y precauciones)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etiqueta de Galantamina, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

In a study of patients with asthma whose bronchodilators were temporarily withheld for assessment, bronchoconstriction and wheezing following AFREZZA dosing was reported in 29% (5/17) and 0% (0/13) of patients with and without a diagnosis of asthma, respectively. (etiqueta de Insulina regular (humana), Advertencias y precauciones)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (etiqueta de Ipratropio, Advertencias y precauciones)

Beta blockers antagonize the bronchodilator effect of beta-receptor agonists. (etiqueta de Labetalol, Interacciones medicamentosas)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (etiqueta de Ipratropio, Advertencias y precauciones)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (etiqueta de Lumateperona, Advertencias y precauciones)

Appropriate care is advised when prescribing LATUDA for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration. (etiqueta de Lurasidona, Advertencias y precauciones)

NAMZARIC may interfere with anticholinergic medications. (etiqueta de Memantina y donepezilo, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

Appropriate care is advised when prescribing ERZOFRI to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration. (etiqueta de Paliperidona, Advertencias y precauciones)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

It is responsive to ephedrine or anticholinergic drugs ( 5.8 ) (etiqueta de Remifentanilo, Advertencias y precauciones)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etiqueta de Rituximab, Advertencias y precauciones)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (etiqueta de Ipratropio, Advertencias y precauciones)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (etiqueta de Ipratropio, Advertencias y precauciones)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

It is difficult to determine if Tolcapone tablets played a role in the pathogenesis of these events because these patients received several concomitant medications affecting the central nervous system such as monoaminergic (i.e., MAO-I, tricyclic and selective serotonin reuptake inhibitors) and anticholinergic agents. (etiqueta de Tolcapona, Precauciones)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etiqueta de Ipratropio, Interacciones medicamentosas)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (etiqueta de Ropinirol, Interacciones medicamentosas)